A carregar...
Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
For most patients with chronic myeloid leukemia, tyrosine kinase inhibitors (TKIs) have turned a fatal disease into a manageable chronic condition. Imatinib, the first BCR-ABL1 TKI granted regulatory approval, has been surpassed in terms of molecular responses by the second-generation TKIs nilotinib...
Na minha lista:
| Publicado no: | J Clin Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Clinical Oncology
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4658454/ https://ncbi.nlm.nih.gov/pubmed/26371140 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.62.4718 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|